At a glance
ClinicalIndex Comparison RecordN/ACompleted· 206 enrolled
Drug / intervention
Aromasin +1 moredrug
Likely dose
Aromasin 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
In Brief
An observational study evaluating Aromasin for Breast Cancer. Completed, enrolled 206 participants across 22 sites.
Detailed Summary
This non-interventional study is to monitor use in real practice in Korea including adverse events on Aromasin (Exemestane).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2010
Enrollment StartJun 2010
Primary CompletionJun 2014
TodayJul 2026
First PostedJan 12, 2010
Enrollment StartJun 1, 2010
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 16.5 years ago
Interventions
Aromasindrug
25 mg table QD
Aromasindrug
25 mg table QD